-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GMA-102 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GMA-102 in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GMA-102 in Type 2 Diabetes Drug Details: GMA-102 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GMA-301 in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GMA-301 in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GMA-301 in Pulmonary Arterial Hypertension Drug Details: GMA-301 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GMA-105 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GMA-105 in Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GMA-105 in Obesity Drug Details: GMA-105 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tusamitamab Ravtansine in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tusamitamab Ravtansine in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Drug Details: Tusamitamab ravtansine is under development...
-
Product Insights
Port Gregory Garnet Mine
The Port Gregory Garnet Mine is a garnet mine in Australia. It is currently in operation. Empower your strategies with our Port Gregory Garnet Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986209 in Thrombosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986209 in Thrombosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BMS-986209 in ThrombosisDrug Details:BMS-986209 is under development for the treatment of thrombotic disorders. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Buntanetap Tartrate in Frontotemporal Dementia (FTD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Buntanetap Tartrate in Frontotemporal Dementia (FTD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Buntanetap Tartrate in Frontotemporal Dementia (FTD)Drug Details:Buntanetap (ANVS-401 (Posiphen)) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Siremadlin Succinate in Secondary Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Siremadlin Succinate in Secondary Acute Myeloid Leukemia Drug Details: Siremadlin succinate (HDM-201) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zimberelimab in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zimberelimab in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Zimberelimab in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:Zimberelimab (Sepalizumab)...